AdvanCell: Funding, Investors & Team (Sep 2026)
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes attached to molecules, which can deliver targeted radiation to tumors at the molecular level. This approach enables healthcare providers to offer safe and efficient treatment options for various types of cancer.
AdvanCell has raised $438M across 3 funding rounds on record, the most recent a Series D of $315M announced in Jul 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
AdvanCell Company Profile and Key Stats
Latest funding round on record: Jul 2026.
AdvanCell Funding Rounds
AdvanCell raised $112M in a Series C announced in Feb 2025.
2 months later, an undisclosed round of $11.3M was announced in Apr 2025.
1.3 years later, a Series D of $315M was announced in Jul 2026.
AdvanCell Investors
22 investors are recorded in total; the 5 named above are those the record identifies.
AdvanCell Founders and Leadership Team
Contact details for the AdvanCell team: 2 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →AdvanCell Funding Compared to Other Biotechnology Startups
AdvanCell's latest round of $315M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like AdvanCell in Biotechnology and Sydney
Companies Similar to AdvanCell
The objective of Fluent is to seamlessly integrate humans with AI, improving interaction and communication…
Mesoblast is a developer of biologic products for the broad field of regenerative medicine. Mesoblast's…
Microba Life Sciences Ltd. provides consumers, doctors, and researchers with gut microbiome testing services…
Algenie was founded on a simple realization: algae has the potential to save the earth, but only if it is…
Paradigm Pharmaceuticals is a global biopharmaceutical company driven to discover, develop, and deliver…
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
BiomeBank’s mission is to treat and prevent disease by restoring gut microbial ecology
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing…
Cauldron Ferm is a technique that speeds up the production of precision fermented prototypes to commercial…
HydGene Renewables is developing a biotechnology platform that produces on-site green hydrogen from waste…
Swan Genomics is focused on commercialising an innovative new approach to DNA sequencing to deliver more…
OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to…
AdvanCell Funding FAQs
What does AdvanCell do?
AdvanCell is a company that focuses on developing innovative cancer treatments using alpha-emitting isotopes attached to molecules, which can deliver targeted radiation to tumors at the molecular level. This approach enables healthcare providers to offer safe and efficient treatment options for various types of cancer.
How much funding has AdvanCell raised?
AdvanCell has raised $438M across 3 rounds on record. The most recent is a Series D of $315M announced in Jul 2026.
When did AdvanCell last raise funding?
AdvanCell's most recent funding round on record is a Series D of $315M, announced in Jul 2026.
Who has invested in AdvanCell?
Investors on record for AdvanCell include Eli Lilly, Alpha Wave Global, Fidelity, Sanofi Ventures, Catalio Capital Management. FundedIQ records 22 investors in total.
Who founded AdvanCell?
FundedIQ lists Andrew Adamovich (Founder) at AdvanCell.
Who is the CEO of AdvanCell?
Philina Lee is listed as Chief Executive Officer at AdvanCell.
Where is AdvanCell headquartered?
AdvanCell is based in Sydney, New South Wales, Australia.
How many employees does AdvanCell have?
AdvanCell is in the 11-50 employee band.
When was AdvanCell founded?
AdvanCell was founded in 2019.
How does AdvanCell's funding compare to other Biotechnology startups?
AdvanCell's latest round of $315M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's AdvanCell Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for AdvanCell is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.